# IvaBradinE to Treat MicroalbumiNuria in Patients With Type 2 Diabetes and Coronary Heart Disease

> **NCT03105219** · PHASE3 · WITHDRAWN · sponsor: **Nanjing First Hospital, Nanjing Medical University**

## Conditions studied

- Diabetic Kidney Disease

## Interventions

- **DRUG:** Ivabradine
- **OTHER:** Sham Comparator

## Key facts

- **NCT ID:** NCT03105219
- **Lead sponsor:** Nanjing First Hospital, Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2017-07-01
- **Primary completion:** 2021-05-30
- **Final completion:** 2021-05-30
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Shortfall in funding
- **Last updated:** 2020-11-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03105219

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03105219, "IvaBradinE to Treat MicroalbumiNuria in Patients With Type 2 Diabetes and Coronary Heart Disease". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03105219. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*